Skip to Content
Merck

IFITM3 requires an amphipathic helix for antiviral activity.

EMBO reports (2017-08-25)
Nicholas M Chesarino, Alex A Compton, Temet M McMichael, Adam D Kenney, Lizhi Zhang, Victoria Soewarna, Matthew Davis, Olivier Schwartz, Jacob S Yount
ABSTRACT

Interferon-induced transmembrane protein 3 (IFITM3) is a cellular factor that blocks virus fusion with cell membranes. IFITM3 has been suggested to alter membrane curvature and fluidity, though its exact mechanism of action is unclear. Using a bioinformatic approach, we predict IFITM3 secondary structures and identify a highly conserved, short amphipathic helix within a hydrophobic region of IFITM3 previously thought to be a transmembrane domain. Consistent with the known ability of amphipathic helices to alter membrane properties, we show that this helix and its amphipathicity are required for the IFITM3-dependent inhibition of influenza virus, Zika virus, vesicular stomatitis virus, Ebola virus, and human immunodeficiency virus infections. The homologous amphipathic helix within IFITM1 is also required for the inhibition of infection, indicating that IFITM proteins possess a conserved mechanism of antiviral action. We further demonstrate that the amphipathic helix of IFITM3 is required to block influenza virus hemagglutinin-mediated membrane fusion. Overall, our results provide evidence that IFITM proteins utilize an amphipathic helix for inhibiting virus fusion.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
17-Octadecynoic acid, ≥95% (GC)
Millipore
EZview Red Anti-c-Myc Affinity Gel
Sigma-Aldrich
Brij® O10
Sigma-Aldrich
N-p-Tosyl-L-phenylalanine chloromethyl ketone, ≥97% (TLC), powder
Sigma-Aldrich
ECO BRIJ® O10